Quick Answer
ROCKET PHARMACEUTICALS, INC. reported Diluted EPS of $2.01 per share (loss) for fiscal year 2025.
ROCKET PHARMACEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.01 | +26.4% |
| 2024 | -$2.73 | +6.5% |
| 2023 | -$2.92 | +10.4% |
| 2022 | -$3.26 | -22.1% |
| 2021 | -$2.67 | -6.0% |
| 2020 | -$2.52 | -59.5% |
| 2019 | -$1.58 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.45 | +36.6% | +27.4% |
| June 30, 2025 | -$0.62 | +16.2% | -10.7% |
| March 31, 2025 | -$0.56 | +15.2% | +21.1% |
| September 30, 2024 | -$0.71 | +5.3% | +4.1% |
| June 30, 2024 | -$0.74 | +9.8% | -12.1% |
| March 31, 2024 | -$0.66 | +9.6% | +12.0% |
| September 30, 2023 | -$0.75 | +13.8% | +8.5% |
| June 30, 2023 | -$0.82 | +1.2% | -12.3% |
- ROCKET PHARMACEUTICALS, INC. showed an increase of +26.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, ROCKET PHARMACEUTICALS, INC.’s diluted eps has declined by 27.2% (from $1.58 per share (loss) to $2.01 per share (loss)).
- The most recent figure is from ROCKET PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: